CXCR2 and neoplasm: We also examined the expression of CD38, CD33, and CXCR2 in tumor tissues of TE10 tumor-bearing hu-HSC-NOG-EXL mice treated with AZD4547 10 mg/kg for 21 d and AZD4547 treatment significantly reduced the CD38, CD33, and CXCR2 levels in tumor tissues (Figure 5G).